Shanghai Unveils Action Plan and Fund for Biopharma M&A Activities
The Shanghai Municipal People’s Government has released the “Action Plan for Supporting Mergers and Acquisitions...
Policy / Regulatory
Beijing Expands Medical Insurance Sharing to Near Relatives with New Policy
The Beijing Municipal Medical Insurance Bureau has released a notification that significantly expands the scope...
CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency
The Center for Drug Evaluation (CDE) in China has announced the selection of the 89th...
NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao
The National Medical Products Administration (NMPA) has issued the “Notification on Simplifying the Registration and...
China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism
The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...
NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 85th batch of reference drugs for...
China’s Health Commission Issues Guidelines to Strengthen Ties Between Healthcare and Elderly Care
The National Health Commission, in conjunction with three other bureaus, has issued the “Notice on...
Hefan Medicine’s Piracetam Production and Marketing Suspended Over GMP Violations
The National Drug Alliance Procurement Office has issued a notification to suspend the manufacturing and...
China’s NHC Launches Pilot Plan to Expand Wholly Foreign-Owned Hospital Sector
The National Health Commission (NHC) has released the “Pilot Work Plan for Expanding the Wholly...
NMPA Drafts Medical Representative Management Measures, Seeks Public Input
The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”,...
Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition
On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded...
National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs
The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...
China’s NHC Aims to Enhance Continuity of Medical Services with Referral System by 2030
The National Health Commission (NHC) has released a notification aimed at enhancing the continuity of...
NHSA Issues Guidelines to Suspend Direct Online Listing of In-Shortage Drugs
The National Healthcare Security Administration (NHSA) has issued the “Guidelines for Risk Management of In-Shortage...
NHC Aims for Nationwide Inspection Result Sharing in Medical Consortia by 2030
The National Healthcare Commission (NHC) has issued the “Guiding Opinions on Further Promoting Mutual Recognition...
AstraZeneca’s ALXN1850 (Efzimfotase Alfa) Selected for China’s Rare Disease Care Plan
The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...
NHSA to Announce NRDL Adjustment Results at November 28th Press Conference
The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...
NMPA and Local Governments Streamline Drug Approval Processes in China
The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...
National Allied Procurement Office Announces Round 10 VBP Tender Program with New Rules
The National Allied Procurement Office has released a notification regarding Round 10 of the national...
Jiangsu Chia Tai Fenghai’s ALS Treatment FHND1002 Selected for CDE’s Patient-Centered Care Plan
China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai...